Cf. Lanata et al., SAFETY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF ONE AND 3 DOSES OFTHE TETRAVALENT RHESUS ROTAVIRUS VACCINE IN INFANTS IN LIMA, PERU, The Journal of infectious diseases, 174(2), 1996, pp. 268-275
An oral rhesus-human rotavirus tetravalent (RRV-TV) vaccine (10(4) pfu
of rhesus rotavirus [type G3] and of 3 human-rhesus reassortants [G1,
G2, and G4]) was evaluated in a field trial in Lima, Peru. At 2, 3, a
nd 4 months of age, infants received either a dose of RRV-TV, an initi
al dose of vaccine followed by a dose of placebo at 3 and 4 months, or
a dose of placebo. Rotavirus-specific IgA responses were detected by
ELISA in 75% of the three-dose vaccine group, 59% of the one-dose vacc
ine group (P = .05), and 24% of the placebo group (P < .001): 64%, 48%
, and 12% of each group, respectively, had a neutralizing antibody res
ponse to at least 1 serotype. Both one and three doses of vaccine fail
ed to induce a significant level of protection against rotavirus diarr
hea; however, they did provide some protection (range, 35%-66%) agains
t more severe rotavirus diarrhea, especially for episodes caused by ty
pe G1.